← Back to Search

Anticoagulant

Dalteparin for Deep Vein Thrombosis (WAVe Trial)

Phase 2
Waitlist Available
Led By Marc Carrier, MD
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 180
Awards & highlights

WAVe Trial Summary

This trial is testing whether it is safe to give cancer patients who weigh more than 90 kg the same low molecular weight heparin injections (LMWH), regardless of their weight.

Eligible Conditions
  • Deep Vein Thrombosis (DVT)
  • Cancer
  • Obesity

WAVe Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 180
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 180 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Major bleeding episode
Secondary outcome measures
Bioaccumulation of study drug
Clinically relevant non major bleeding events
Minor bleeding events
+2 more

Side effects data

From 2014 Phase 4 trial • 87 Patients • NCT00966277
59%
Nausea
47%
Constipation
44%
Vomiting
35%
Abdominal pain
24%
Bruising/minor bleeding
18%
Dyspnea
18%
Myalgia
12%
Anxiety
9%
Bone pain
6%
Dermatology/Skin (Other)
6%
Ocular/Visual (Other)
3%
Insomnia
3%
Allergic rhinitis
3%
Depression
100%
80%
60%
40%
20%
0%
Study treatment Arm
Group 1: Dalteparin
Group 2: Control

WAVe Trial Design

1Treatment groups
Experimental Treatment
Group I: Weight adjusted dalteparinExperimental Treatment1 Intervention
Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month. 91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU) ≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dalteparin
FDA approved

Find a Location

Who is running the clinical trial?

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) NetworkNETWORK
10 Previous Clinical Trials
17,371 Total Patients Enrolled
1 Trials studying Deep Vein Thrombosis
1,500 Patients Enrolled for Deep Vein Thrombosis
Ottawa Hospital Research InstituteLead Sponsor
559 Previous Clinical Trials
2,785,460 Total Patients Enrolled
11 Trials studying Deep Vein Thrombosis
4,089 Patients Enrolled for Deep Vein Thrombosis
Marc Carrier, MDPrincipal InvestigatorOttawa Hospital Research Institute
4 Previous Clinical Trials
1,501 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are recruitment efforts for this experiment still underway?

"The trial, which can be found on clinicaltrials.gov, is currently looking for patients to participate. The study was posted on 3/21/2018 and updated on 1/12/2021."

Answered by AI

Can you tell me how many locations are participating in this trial?

"Currently, this study is being conducted in 5 hospitals; 3 of which are located in Edmonton, Hamilton and Toronto. The other 2 sites are situated in other cities. If you enroll, it would be convenient to choose the location nearest to you to avoid any unnecessary travel."

Answered by AI

What is the potential severity of side effects for Dalteparin?

"Dalteparin is a Phase 2 drug, meaning that while there is evidence for its safety, there is none yet for its efficacy. We gave it a score of 2."

Answered by AI

Are there other similar medical experiments that have used Dalteparin?

"Dalteparin was first trialed in 2016 at Hackensack University Medical Center. So far, there have been a total of 42 completed trials worldwide. Currently, 12 more dalteparin trials are being conducted; many of these are out of Edmonton, Alberta."

Answered by AI

Can you explain Dalteparin's typical application?

"Dalteparin, while most commonly used as a treatment for venous thromboembolism, can also be effective in other scenarios such as deep vein thrombosis, general surgery, and hemodialysis."

Answered by AI

What is the patient intake for this clinical trial?

"That is correct, the clinicaltrials.gov website does show that this trial is still looking for patients. The listing was first put up on March 21st, 2018 and updated as recently as January 12th, 2021. They are hoping to find 150 individuals total from 5 different sites."

Answered by AI
~13 spots leftby Mar 2025